



# MINUTES

Utah Department of Health  
Pharmacy and Therapeutics Committee

Thursday, October 19, 2017  
7:15 a.m. to 8:45 a.m.  
Cannon Health Building  
Room 128

**Committee Members Present:**

Bryan Larson, PharmD  
Clayton Grace, RPh  
Elizabeth Young, PharmD

Jake Jones, MD  
Keith Tolman, MD

**Committee Members Excused:**

Clinton Sheffield, MD  
Abril Atherton, PharmD

Susan Siegfried, MD

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Sue Leong, RPh., Pharmacy Director  
Andrea Rico, CPhT

Merelynn Berrett, RN  
Robyn Seely, PharmD

**University of Utah Drug Regimen Review Center Staff Presenter:**

Elena Martinez Alonso, BPharm, MSc MTSI, Medical Writer

**Other Individuals Present:**

Cody Ball, SelectHealth  
Lori Howarth, Bayer  
Charissa Anne, J&J

Natalie Thornock, TEVA  
Jennifer Lauper, Bristol Myers Squibb

Meeting conducted by: Committee Chair

---

1. **Welcome & Housekeeping:** Bryan Larson opened the meeting and reminded everyone to sign the rosters.
2. **Review and Approval of September Minutes:** Elizabeth Young made a motion to approve the minutes from September. Clayton Grace seconded the motion. Unanimous Approval.
3. **Drug Utilization Review (DUR) Board update:** The DUR board met last week to discuss Pediatric Antibiotic Use
4. **Long-Acting  $\beta$ -2 Agonist & Glucocorticoid Combinations:** Elena Martinez Alonso presented a review of Long-Acting Beta-2 Agonist & Glucocorticoid Combinations. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.

5. **Public Comment:** Bryan Larson read a letter in the absence of Maria Agapova, MSC, PhD, Teva Pharmaceuticals, regarding AirDuo,
6. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other states' Medicaid programs.
7. **Committee Discussion:** Elizabeth Young stated the review of the Long-Acting  $\beta$ -2 Agonist & Glucocorticoid Combinations was well presented and conclusive. She also suggested there is no real need for adjustments to the medications listed on PDL. Keith Tolman concurred.
8. **Public Meeting Adjourned:** Bryan Larson motioned to close the meeting. Keith Tolman seconded the motion. Unanimous Approval.
9. **Next meeting is scheduled for** November 16, 2017 DPP-4 Inhibitors.

---

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>